A new drug has been approved by the NHS to help those with Leukaemia. The BBC ran this story and noted that, Cardiff University trials showed it can reduce the risk of death by 59% by preventing cancer cells multiplying. 
This is an incredible break-through for patients with Chronic lymphocytic leukaemia (CLL) – a form of blood cancer. This type of cancer targets those that already suffer with other relatable conditions such as, diabetes and heart disease. Therefore if the drug is successful, sufferers will stand a high chance at battling the cancer if they find it at early stages.
If patients suffer heavily with other conditions, this usually means they cannot receive aggressive treatment. However this drug allows a mild, yet effective way to protect the body.
Prof Chris Fegan, who led the trials at Cardiff University said: “Gazyvaro is a tolerable option that can not only keep these patients in remission for significantly longer, but offers a survival benefit over the current standard.” 
This is great news for CLL sufferers, for around 3,100 are diagnosed in the UK per year. However, CLL is different from most cancers, as it is not usually possible to cure.
To conclude, Gazyvaro is a remarkable drug to even reach the testing stages. We can only hope it succeeds in helping those who suffer.
What are you thoughts on this new medical development? Do you entrust the drug is a new era for medicine?
 BBC News, (2014). NHS leukaemia drug watchdog ‘U-turn’. Available at: http://www.bbc.co.uk/news/uk-wales-30274804 [Accessed 3 Dec. 2014].